Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GULLIVER-2: GB1211 in Hepatic Impairment
NCT05009680Phase 2Unknown
- Sponsor
- Galecto, Inc.
- Start
- Sep 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selvigaltin in Liver cirrhosis (LC), sponsored by Galecto, Inc.. Status: unknown.
02
Drugs
selvigaltin
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT05009680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05009680.